Levofloxacin + AzithromycinThird Party Manufacturing in India

Levofloxacin + Azithromycin is a broad-spectrum antibiotic combination that works through two complementary mechanisms to eradicate bacterial infections. Levofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA replication by targeting DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA supercoiling and chromosomal separation during cell division. By stabilizing the cleaved DNA-enzyme complex, levofloxacin prevents the resealing of the DNA strands, leading to irreversible bacterial DNA damage and cell death. Azithromycin, a macrolide antibiotic, acts by binding to the 50S ribosomal subunit of susceptible bacteria. It specifically attaches to the 23S rRNA of the 50S subunit and blocks the transpeptidation and translocation steps of protein synthesis. This inhibition prevents the growing peptide chain from extending, halting bacterial protein production. Together, these two agents provide synergistic coverage against gram-positive, gram-negative, and atypical respiratory pathogens, reducing the likelihood of bacterial resistance development.

Levofloxacin + Azithromycin third party manufacturing in India meets the growing demand for potent fixed-dose antibiotic combinations used in the management of community-acquired infections. This pharmaceutical product combines two established antibiotics with proven efficacy and safety profiles.

Therapeutic Uses

Levofloxacin + Azithromycin is prescribed for the treatment of:

• Community-Acquired Pneumonia: Effective against Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.
• Acute Bacterial Sinusitis: Provides broad coverage against the most common sinus pathogens, including both typical and atypical bacteria.
• Acute Exacerbations of Chronic Bronchitis: Addresses the polymicrobial nature of exacerbations with dual-mechanism coverage.
• Upper and Lower Respiratory Tract Infections: Covers a wide spectrum of respiratory pathogens resistant to single-agent therapy.
• Atypical Pneumonia: Azithromycin's activity against atypical organisms complements levofloxacin's potent gram-negative coverage.

Why Choose a Levofloxacin + Azithromycin Manufacturer in India

This fixed-dose combination addresses the urgent clinical need for effective empirical therapy in respiratory infections. For pharmaceutical brands and distributors, sourcing from an WHO-GMP certified Levofloxacin + Azithromycin manufacturer ensures production under stringent quality standards. Indian manufacturers offer significant cost advantages without compromising on quality, making this combination accessible in both domestic and international markets across Asia, Africa, and Latin America. The established manufacturing infrastructure for macrolides and fluoroquinolones in India ensures reliable supply and consistent product quality.